LUMINA
| Clinical Trial Title | LUMINA |
| Trial Status | Open to Enrollment |
| Start Date | 05/01/2019 |
| Location | legacy-good-samaritan-medical-center |
| Trial Type | Ophthalmology |
| Specific Condition | Active, Non-Infectious Uveitis |
| Description | This is a Phase III study to assess the efficacy and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye. There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control. |
| Eligibility Criteria | Ages Eligible for Study: 18 years and older
Sexes Eligible for Study: All Criteria
Inclusion Criteria: Non-Infectious Active Uveitis of the Posterior Segment Exclusion Criteria: Females who are pregnant, nursing, or planning a pregnancy Confirmed or suspected infectious uveitis |
| IRB Number | 10828 |
| Notes | |
| Principal Investigator | Sirichai Pasadhika, MD |
| Contact Name | Tammy Mayfield |
| Contact Phone | 503-413-7945 |
| Contact Fax | 503-413-6861 |
| Contact E-Mail | tmayfiel@lhs.org |
